SpyBiotech and The University of Oxford have entered a research agreement to develop a vaccine against Epstein-Barr virus (EBV). EBV is a widespread virus that can cause various health conditions, including infectious mononucleosis, and is associated with certain cancers and multiple sclerosis.
The collaboration will leverage Oxford’s academic research expertise and SpyBiotech’s proprietary SPYVLP vaccine platform. The project aims to advance three vaccine candidates targeting EBV and conduct a Phase I clinical trial.
Mark Leuchtenberger, CEO of SpyBiotech, indicated that the research is crucial for addressing a highly prevalent virus where no vaccines or therapeutics currently exist and that EBV is linked to severe health conditions, and they believe their SPYVLP platform can provide an effective solution.
SpyBiotech’s SPYVLP platform utilizes a protein “superglue” technology to bind antigens to vaccine delivery platforms. This approach minimizes delivery risks while enhancing immunogenicity and efficacy.
Oxford researchers will have access to the SPYVLP platform and will work towards Phase I clinical trials. “We are eager to progress these vaccine candidates into Phase I trials based on promising pre-clinical data,” said Sumi Biswas, President and CSO of SpyBiotech.
SpyBiotech is currently conducting a Phase I trial for its HCMV vaccine to assess safety and immunogenicity. The company also has a diverse pipeline targeting other infectious diseases, such as respiratory syncytial virus (RSV) and cytomegalovirus (CMV).
EBV affects a vast majority of the population and can have serious consequences for some individuals. This collaboration between SpyBiotech and Oxford University has the potential to make significant strides in preventing and treating EBV-related illnesses.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
